Brain radiation timing study for gene-mutated lung cancer
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study compares giving brain radiation right away versus waiting, in people with lung cancer that has an EGFR or ALK gene change and has spread to the brain but causes no symptoms. It aims to see which approach helps control the brain cancer better and keeps quality of life stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older.
- Your general ability to function is good (ECOG 0 to 2).
- You have non–small cell lung cancer confirmed by pathology (biopsy/test results).
- Your tumor has an EGFR or ALK gene mutation.
- You have brain metastases seen on scans, and you have no brain-related symptoms.
- You’re able and willing to sign consent and follow the study visit schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether it is better to delay brain radiation or give it right away in people with ALK-positive lung cancer that has spread to the brain and is causing few or no symptoms. If you are starting alectinib, you may be able to join and help find the best timing for radiation.
This trial looks at whether the timing of radiation therapy and immunotherapy (like Keytruda or Opdivo) affects outcomes in patients with non-small cell lung cancer (NSCLC) that has spread to the brain. You would receive both treatments as part of your normal care, and the study will track how you do.
This Phase 3 study tests whether giving brain radiation early or later, along with almonertinib (a targeted pill), works better for people with EGFR-mutated non-small cell lung cancer that has a small number of brain metastases. It aims to control brain disease while checking safety and effectiveness in a carefully selected group.
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
This Phase 2 trial studies whether giving immunotherapy along with a precise form of brain radiation can control brain metastases from non-small cell lung cancer. It may help by shrinking or stabilizing spots in the brain while your body’s immune system is also activated.
This trial tests if adding stereotactic radiosurgery (focused radiation) to standard drug therapy is safe and effective for people with EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to improve control of brain metastases while continuing targeted therapy.
Hear when a new Asymptomatic Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.